Insider Transactions in Q2 2023 at Acrivon Therapeutics, Inc. (ACRV)
Insider Transaction List (Q2 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 26
2023
|
Chione LTD > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
16
-0.0%
|
$192
$12.93 P/Share
|
|
Jun 16
2023
|
Rasmus Holm Jorgensen Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,500
+24.34%
|
$28,500
$3.63 P/Share
|
|
Jun 15
2023
|
Chione LTD > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
2,056
-0.05%
|
$24,672
$12.14 P/Share
|
|
Jun 14
2023
|
Chione LTD > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
893
-0.02%
|
$10,716
$12.13 P/Share
|
|
Jun 13
2023
|
Chione LTD > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
3,000
-0.08%
|
$36,000
$12.3 P/Share
|
|
Jun 12
2023
|
Chione LTD > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
2,000
-0.05%
|
$24,000
$12.34 P/Share
|
|
Jun 05
2023
|
Eric Devroe Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,225
+12.79%
|
$9,225
$1.04 P/Share
|
|
May 31
2023
|
Peter Blume Jensen President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
33,605
+1.38%
|
$100,815
$3.88 P/Share
|